Page 52 - Amgen News Today

Amgen Inc. (NASDAQ:AMGN – Get Free Report) SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now directly owns 9,883 shares […]

Axxcess Wealth Management LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 11.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,362 shares of the medical research company’s stock after purchasing an additional 1,518 shares during the […]

The market rally to close the week was brought to you by the letter "A." Two Dow components, Apple and Amgen, accounted for about 50% of the gains in the NYSE…

Barclays upgraded shares of Amgen (NASDAQ:AMGN – Free Report) from an underweight rating to an equal weight rating in a research report report published on Friday, MarketBeat reports. The firm currently has $300.00 price objective on the medical research company’s stock, up from their previous price objective of $230.00. Several other analysts have also issued […]

Amgen (NASDAQ:AMGN – Free Report) had its price target boosted by UBS Group from $284.00 to $307.00 in a report released on Friday, Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock. AMGN has been the subject of a number of other reports. William Blair upgraded Amgen from a […]

Amgen (NASDAQ:AMGN – Free Report) had its target price reduced by Royal Bank of Canada from $332.00 to $328.00 in a report issued on Friday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the medical research company’s stock. Several other research analysts also recently commented on AMGN. SVB Leerink downgraded […]

Amgen (NASDAQ:AMGN – Free Report) had its price objective decreased by Royal Bank of Canada from $332.00 to $328.00 in a research report report published on Friday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the medical research company’s stock. Several other equities analysts have also weighed in on the […]

By Deena Beasley (Reuters) - Amgen reported a slightly lower first-quarter profit on Thursday, citing higher operating and interest expense from its recent acquisition of rare disease drugmaker Horizon Therapeutics, partially offset by double-digit...

Amalgamated Bank reduced its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 131,376 shares of the medical research company’s stock after selling 6,666 shares during the period. […]

The major averages are on track for modest declines on the week as Wall Street awaits the April jobs report.